FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891512380> ?p ?o ?g. }

• W2891512380 endingPage "38" @default.
• W2891512380 startingPage "27" @default.
• W2891512380 abstract "Immunoglobulin (Ig) G- and IgM-class anti-cardiolipin antibodies (aCL) and lupus anti-coagulant (LA) are included in the 1997 update of the American College of Rheumatology (ACR-97) systemic lupus erythematosus (SLE) criteria. Despite limited evidence, IgA-aCL and IgA anti-β2 -glycoprotein-I (anti-β2 GPI) were included in the 2012 Systemic Lupus International Collaborating Clinics criteria. The present study aimed to evaluate IgG-/IgA-/IgM-aCL and anti-β2 GPI occurrence in relation to disease phenotype, smoking habits, pharmacotherapy, anti-phospholipid syndrome (APS) and organ damage among 526 Swedish SLE patients meeting ACR-97. Patients with rheumatoid arthritis (n = 100), primary Sjögren's syndrome (n = 50) and blood donors (n = 507) served as controls. Anti-phospholipid antibodies (aPL) were analysed by fluoroenzyme-immunoassays detecting aCL/anti-β2 GPI. Seventy-six (14%) SLE cases fulfilled the Sydney APS-criteria, and ≥ 1 aCL/anti-β2 GPI isotype (IgG/IgA/IgM) occurred in 138 SLE patients (26%). Forty-five (9%) of the SLE cases had IgA-aCL, 20 of whom (4%) lacked IgG-/IgM-aCL. Seventy-four (14%) tested positive for IgA anti-β2 GPI, 34 (6%) being seronegative regarding IgG/IgM anti-β2 GPI. Six (1%) had APS manifestations but were seropositive regarding IgA-aCL and/or IgA anti-β2 GPI in the absence of IgG/IgM-aPL and LA. Positive LA and IgG-aPL tests were associated with most APS-related events and organ damage. Exclusive IgA anti-β2 GPI occurrence associated inversely with Caucasian ethnicity [odds ratio (OR) = 0·21, 95% confidence interval (CI) = 0·06-0·72) and photosensitivity (OR = 0·19, 95% CI = 0·05-0·72). Nephritis, smoking, LA-positivity and statin/corticosteroid-medication associated strongly with organ damage, whereas hydroxychloroquine-medication was protective. In conclusion, IgA-aPL is not rare in SLE (16%) and IgA-aPL analysis may have additional value among SLE cases with suspected APS testing negative for other isotypes of aPL and LA." @default.
• W2891512380 created "2018-09-27" @default.
• W2891512380 creator A5001732862 @default.
• W2891512380 creator A5003939250 @default.
• W2891512380 creator A5026190790 @default.
• W2891512380 creator A5037276492 @default.
• W2891512380 creator A5039395176 @default.
• W2891512380 creator A5039777981 @default.
• W2891512380 creator A5048984979 @default.
• W2891512380 creator A5053954343 @default.
• W2891512380 creator A5057374732 @default.
• W2891512380 creator A5074915771 @default.
• W2891512380 creator A5085860930 @default.
• W2891512380 creator A5088690481 @default.
• W2891512380 date "2018-09-12" @default.
• W2891512380 modified "2023-10-12" @default.
• W2891512380 title "Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual" @default.
• W2891512380 cites W1837874984 @default.
• W2891512380 cites W1868564266 @default.
• W2891512380 cites W1940591286 @default.
• W2891512380 cites W1953041691 @default.
• W2891512380 cites W1973782940 @default.
• W2891512380 cites W1975074770 @default.
• W2891512380 cites W1986294700 @default.
• W2891512380 cites W1992325618 @default.
• W2891512380 cites W1995365224 @default.
• W2891512380 cites W2002239489 @default.
• W2891512380 cites W2023569640 @default.
• W2891512380 cites W2030684251 @default.
• W2891512380 cites W2037917671 @default.
• W2891512380 cites W2047184949 @default.
• W2891512380 cites W2054330426 @default.
• W2891512380 cites W2054401069 @default.
• W2891512380 cites W2066133643 @default.
• W2891512380 cites W2070527591 @default.
• W2891512380 cites W2077541411 @default.
• W2891512380 cites W2077980358 @default.
• W2891512380 cites W2078790987 @default.
• W2891512380 cites W2079116113 @default.
• W2891512380 cites W2082490188 @default.
• W2891512380 cites W2083893310 @default.
• W2891512380 cites W2092815162 @default.
• W2891512380 cites W2108905161 @default.
• W2891512380 cites W2110593602 @default.
• W2891512380 cites W2110803155 @default.
• W2891512380 cites W2120492526 @default.
• W2891512380 cites W2126478084 @default.
• W2891512380 cites W2131996419 @default.
• W2891512380 cites W2139198208 @default.
• W2891512380 cites W2145438137 @default.
• W2891512380 cites W2148616488 @default.
• W2891512380 cites W2152348310 @default.
• W2891512380 cites W2156821245 @default.
• W2891512380 cites W2159860161 @default.
• W2891512380 cites W2167385753 @default.
• W2891512380 cites W2177646845 @default.
• W2891512380 cites W2297794063 @default.
• W2891512380 cites W2315221323 @default.
• W2891512380 cites W2416636197 @default.
• W2891512380 cites W2466949744 @default.
• W2891512380 cites W2471124590 @default.
• W2891512380 cites W2527939994 @default.
• W2891512380 cites W2538345017 @default.
• W2891512380 cites W2549602432 @default.
• W2891512380 cites W2555199232 @default.
• W2891512380 cites W2606853969 @default.
• W2891512380 cites W2737936804 @default.
• W2891512380 cites W2801010100 @default.
• W2891512380 cites W2803799996 @default.
• W2891512380 cites W3140065251 @default.
• W2891512380 cites W32539372 @default.
• W2891512380 doi "https://doi.org/10.1111/cei.13180" @default.
• W2891512380 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6156819" @default.
• W2891512380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30208508" @default.
• W2891512380 hasPublicationYear "2018" @default.
• W2891512380 type Work @default.
• W2891512380 sameAs 2891512380 @default.
• W2891512380 citedByCount "14" @default.
• W2891512380 countsByYear W28915123802019 @default.
• W2891512380 countsByYear W28915123802020 @default.
• W2891512380 countsByYear W28915123802021 @default.
• W2891512380 countsByYear W28915123802022 @default.
• W2891512380 countsByYear W28915123802023 @default.
• W2891512380 crossrefType "journal-article" @default.
• W2891512380 hasAuthorship W2891512380A5001732862 @default.
• W2891512380 hasAuthorship W2891512380A5003939250 @default.
• W2891512380 hasAuthorship W2891512380A5026190790 @default.
• W2891512380 hasAuthorship W2891512380A5037276492 @default.
• W2891512380 hasAuthorship W2891512380A5039395176 @default.
• W2891512380 hasAuthorship W2891512380A5039777981 @default.
• W2891512380 hasAuthorship W2891512380A5048984979 @default.
• W2891512380 hasAuthorship W2891512380A5053954343 @default.
• W2891512380 hasAuthorship W2891512380A5057374732 @default.
• W2891512380 hasAuthorship W2891512380A5074915771 @default.
• W2891512380 hasAuthorship W2891512380A5085860930 @default.
• W2891512380 hasAuthorship W2891512380A5088690481 @default.
• W2891512380 hasBestOaLocation W28915123801 @default.
• W2891512380 hasConcept C126322002 @default.

• next